Enanta Pharmaceuticals, Inc. (ENTA)
$
6.98
-0.15 (-2.15%)
Key metrics
Financial statements
Free cash flow per share
-3.8511
Market cap
149.2 Million
Price to sales ratio
2.3146
Debt to equity
0.6279
Current ratio
5.2857
Income quality
0.5753
Average inventory
0
ROE
-0.7983
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Enanta Pharmaceuticals, Inc., founded in 1995 and headquartered in Watertown, Massachusetts, focuses on the discovery and development of small molecule drugs aimed at treating viral infections and liver diseases. The company targets various diseases through its research and development efforts, including respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. In its financial operations, the company reported selling, general, and administrative expenses of $57,850,000.00 indicating its operational overhead costs. The operating expenses amount to $189,326,000.00 encompassing various operational costs incurred during the year. Additionally, the company incurred an income tax expense of -$1,743,000.00 reflecting its obligations to tax authorities. Evaluating operational performance, the EBITDA ratio is -1.55 highlighting the company's operational efficiency. Furthermore, the gross profit stands at $67,635,000.00 showcasing the company's profitability from its core operations. Enanta has a collaborative development agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitors, including paritaprevir and glecaprevir for treating chronic hepatitis C virus. In the investment landscape, the stock is affordable at $6.98 making it an appealing option for budget-conscious investors. However, the stock has a low average trading volume of 164,206.00 indicating lower market activity that might attract investors looking for stability. With a market capitalization of $149,208,668.00 the company is classified as a small-cap player, which often appeals to investors seeking growth opportunities within burgeoning enterprises. Enanta Pharmaceuticals, Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its innovative approaches. Moreover, it belongs to the Healthcare sector, driving innovation and growth as it continues to advance its pipeline of drug candidates.
Is Enanta Pharmaceuticals, Inc. (ENTA) a good investment?
Investing in Enanta Pharmaceuticals, Inc. (ENTA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Enanta Pharmaceuticals, Inc. (ENTA)'s stock forecast?
Analysts predict Enanta Pharmaceuticals, Inc. stock to fluctuate between $4.09 (low) and $17.24 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Enanta Pharmaceuticals, Inc.'s market capitalization?
As of 2025-07-10, Enanta Pharmaceuticals, Inc.'s market cap is $149,208,668, based on 21,376,600 outstanding shares.
How does Enanta Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Enanta Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Enanta Pharmaceuticals, Inc. (ENTA) stock?
To buy Enanta Pharmaceuticals, Inc. (ENTA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENTA. Place an order (Market, Limit, etc.).
What is the best time to invest in Enanta Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Enanta Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $67,635,000 | EPS: -$5.48 | Growth: -14.11%.
Where can I find Enanta Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.enanta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Enanta Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Enanta Pharmaceuticals, Inc. stock?
All-time high: $102 (2021-11-05) | All-time low: $4.09 (2025-04-09).
What are the key trends affecting Enanta Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
a month ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved as the only eight-week treatment for adults and pediatric patients three.
businesswire.com
a month ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the “Even.
businesswire.com
2 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 2.
zacks.com
2 months ago
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
2 months ago
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $1.47 per share a year ago.
businesswire.com
3 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025.
zacks.com
5 months ago
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
5 months ago
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.
businesswire.com
5 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024. “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSV.
businesswire.com
7 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the '953 Patent”) i.
See all news
